Clinical Trials

With its world-renowned and award-winning academic team and strong affiliation with the Centre for Heart Rhythm Disorders at the University of Adelaide, the Cardiovascular Centre has been at the forefront of developing new and innovative treatment approaches to heart problems. You may have the opportunity to be involved in one of our clinical trials during the course of your treatment. If you are eligible and willing, our team will discuss this with you in more detail.

Implications of aggressive cardiac risk factor management on the catheter ablation for AF

ANZCTR Trial ID: ACTRN12613000444785

Catheter ablation of atrial fibrillation (AF) has evolved as an effective therapy for drug-refractory AF, and the indications have broadened in recent years. Despite decreased procedural times, reduced complication rates, post-ablation freedom from AF has not improved proportionately in recent years. Metabolic syndrome (MS) and its components, including obesity, hypertension, diabetes, and dyslipidemia in conjunction with obstructive sleep apnoea, excessive alcohol intake and smoking has been associated with increased incidence of AF.

A randomised controlled trial assessing Home-based Education and Learning Program for Atrial Fibrillation (AF)

ANZCTR Trial ID: ACTRN12611000607976


Usability Study to Assess the Reveal LINQ Insertable Cardiac Monitor System

ANZCTR Trial ID: NCT01965899

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

ANZCTR Trial ID: NCT00911508

CABANA Trial has the overall goal of establishing the appropriate roles for medical and ablative intervention for AF.

Page 1 of 3
  • Professor Sanders says...

    Atrial fibrillation is a consequence of several reversible risk factors - high blood pressure, diabetes, obesity, sleep apnoea, and excessive alcohol. Your management of atrial fibrillation must include strict control of these risk factors.